(COCP) Cocrystal Pharma - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US19188J3005
COCP: Antiviral, Treatments, HCV, Influenza, Coronavirus, Norovirus
Cocrystal Pharma, Inc. is a biotechnology company specializing in the discovery and development of antiviral therapies for severe and chronic viral diseases. Utilizing structure-based drug design, the company creates small-molecule inhibitors targeting viral replication. Its pipeline includes CC-31244, a non-nucleoside polymerase inhibitor for hepatitis C virus (HCV) in Phase II trials, and CC-42344, a PB2 inhibitor for influenza in Phase I. Additionally, Cocrystal is developing inhibitors for norovirus, a leading cause of gastroenteritis, leveraging a collaboration with Kansas State University. The company has also partnered with Merck to develop influenza A/B antivirals, enhancing its credibility in the field.
Technically, COCPs stock is below its 20 and 50-day SMAs, indicating bearish momentum. The low average volume and ATR suggest reduced volatility. Fundamentally, with a $17.6M market cap and high P/S ratio, the stock may be undervalued despite its early-stage revenue generation. The 3-month forecast anticipates sideways movement with potential dips, yet upside potential exists pending positive clinical developments.
Additional Sources for COCP Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
COCP Stock Overview
Market Cap in USD | 18m |
Sector | Healthcare |
Industry | Biotechnology |
GiC Sub-Industry | Pharmaceuticals |
IPO / Inception | 2011-05-19 |
COCP Stock Ratings
Growth 5y | -64.7% |
Fundamental | - |
Dividend | 0.0% |
Rel. Strength Industry | 11 |
Analysts | 4.5/5 |
Fair Price Momentum | 1.19 USD |
Fair Price DCF | - |
COCP Dividends
No Dividends PaidCOCP Growth Ratios
Growth Correlation 3m | -76.9% |
Growth Correlation 12m | 23.4% |
Growth Correlation 5y | -89.4% |
CAGR 5y | -27.59% |
CAGR/Max DD 5y | -0.29 |
Sharpe Ratio 12m | -1.51 |
Alpha | 3.25 |
Beta | 0.70 |
Volatility | 67.59% |
Current Volume | 10.3k |
Average Volume 20d | 17k |
As of March 15, 2025, the stock is trading at USD 1.64 with a total of 10,266 shares traded.
Over the past week, the price has changed by -3.33%, over one month by -11.31%, over three months by -18.59% and over the past year by +11.98%.
No, based on ValueRay Analyses, Cocrystal Pharma (NASDAQ:COCP) is currently (March 2025) a stock to sell. It has a ValueRay Growth Rating of -64.67 and therefor a clear technical negative rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of COCP as of March 2025 is 1.19. This means that COCP is currently overvalued and has a potential downside of -27.44%.
Cocrystal Pharma has received a consensus analysts rating of 4.50. Therefor, it is recommend to buy COCP.
- Strong Buy: 1
- Buy: 1
- Hold: 0
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, COCP Cocrystal Pharma will be worth about 1.3 in March 2026. The stock is currently trading at 1.64. This means that the stock has a potential downside of -18.9%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 8.3 | 407.9% |
Analysts Target Price | 8.3 | 407.9% |
ValueRay Target Price | 1.3 | -18.9% |